Appointment of Chief Commercial Officer
IXICO plc has appointed Tanya Voloshen as Chief Commercial Officer, a new senior leadership role based in Boston, USA, aimed at accelerating business development and expanding the company's US presence. Voloshen brings extensive commercial and executive leadership experience from the neuroimaging market, having previously held senior roles at Perceptive Inc., Clario, QMENTA, and ConcertAI, with early career experience at Johnson & Johnson and Sanofi. This strategic hire underscores IXICO's commitment to strengthening its commercial capabilities and driving growth in the global neuroscience imaging sector.
Select text to share a quote on X · sign in to keep highlights & notes in your IXI notes
-Tanya Voloshen, CCO joins IXICO as a member of the Senior Leadership Team with deep commercial and executive leadership experience in the neuroimaging market -
05 February 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has appointed Tanya Voloshen as Chief Commercial Officer (CCO) based in Boston, Massachusetts (USA).
Tanya joins IXICO from Perceptive Inc. a global contract research organisation (CRO) where she held the role as SVP Commercial. Prior to joining Perceptive, Tanya held senior commercial leadership roles for international clinical trial and medical technology companies with a focus on neuroscience and medical imaging including Clario (now part of Thermo Fisher Scientific), QMENTA and ConcertAI. Tanya started her career in the pharmaceutical industry working for Johnson & Johnson and Sanofi.
Bram Goorden, Chief Executive Officer of IXICO, commented: "I am very pleased to welcome Tanya to IXICO as CCO, a newly appointed position in the senior leadership team that reflects a firm and continued commitment to strengthen our commercial capabilities and accelerate growth. Based in Boston, Tanya brings strong commercial leadership experience, established customer relationships and an excellent understanding of the critical contribution that IXICO's technology platform can make in the clinical imaging market."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.